H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Biomea Fusion to $37 from $44 and keeps a Buy rating on the shares after the company presented new preclinical data from its menin and FLT3 programs evaluating BMF-219 and BMF-500 in liquid tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
- Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting
- Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Biomea Fusion closes upsized common stock offering of $172.5M
- Fly Insider: Planet Labs, C3.ai among week’s notable insider trades